Literature DB >> 21383331

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

T T Batchelor1, S A Grossman, T Mikkelsen, X Ye, S Desideri, G J Lesser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21383331      PMCID： PMC3059144          DOI： 10.1212/WNL.0b013e31820f2d94

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

Review 1.  Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.

Authors:  Roelien H Enting; Alexis Demopoulos; Lisa M DeAngelis; Lauren E Abrey
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910

2.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

3.  Imaging of central nervous system lymphomas with iodine-123 labeled rituximab.

Authors:  Markus Dietlein; Hendrik Pels; Holger Schulz; Oliver Staak; Peter Borchmann; Klaus Schomäcker; Thomas Fischer; Wolfgang Eschner; Elke Pogge von Strandmann; Harald Schicha; Andreas Engert; Roland Schnell
Journal:  Eur J Haematol       Date:  2005-04       Impact factor: 2.997

4.  Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.

Authors:  Gaurav D Shah; Joachim Yahalom; Denise D Correa; Rose K Lai; Jeffrey J Raizer; David Schiff; Renato LaRocca; Barbara Grant; Lisa M DeAngelis; Lauren E Abrey
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

5.  First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.

Authors:  Sofiane Maza; Philipp Kiewe; Dieter L Munz; Agnieszka Korfel; Bernd Hamm; Kristoph Jahnke; Eckhard Thiel
Journal:  Neuro Oncol       Date:  2008-12-05       Impact factor: 12.300
  5 in total
  68 in total

1.  Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.

Authors:  Jorg Dietrich; Laura Versmee; Jan Drappatz; April F Eichler; Lakshmi Nayak; Andrew Norden; Eric Wong; Michelle R Pisapia; SooAe S Jones; Amanda B Gordon; Bruce A Chabner; Fred Hochberg; Tracy T Batchelor
Journal:  Oncologist       Date:  2020-07-01

2.  A 60-year-old Indian male with altered sensorium and extensive lymphoma of the scalp.

Authors:  Budhi S Yadav; Anshuma Bansal; Suresh C Sharma; Pankaj Malhotra; Nilanjan Ghosh; Matthias Holdhoff; Andrei Shustov; Marc Chamberlain; Herbert Newton; Priya Kumethkar; Jeffrey N Raizer; Jon Glass; Gloria J Morris
Journal:  Semin Oncol       Date:  2013-06       Impact factor: 4.929

3.  Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.

Authors:  Roy E Strowd; Inas A Abuali; Stuart A Grossman
Journal:  CNS Oncol       Date:  2015-04-23

4.  Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases.

Authors:  Jing Liu; Xue-Fei Sun; Jun Qian; Xue-Yan Bai; Hong Zhu; Q U Cui; Xiao-Yan Li; Yue-Dan Chen; Ya-Ming Wang; Yuan-Bo Liu
Journal:  Mol Clin Oncol       Date:  2015-05-12

Review 5.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

Review 6.  Primary central nervous system lymphoma: essential points in diagnosis and management.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

7.  Intravascular large B-cell lymphoma presenting as an isolated cauda equina-conus medullaris syndrome - A case report.

Authors:  Yang Yu; Raghav Govindarajan
Journal:  J Spinal Cord Med       Date:  2018-10-22       Impact factor: 1.985

8.  Reply to M.C. Chamberlain.

Authors:  James L Rubenstein; Bruce D Cheson; Sin-Ho Jung; Lawrence D Kaplan
Journal:  J Clin Oncol       Date:  2014-02-03       Impact factor: 44.544

9.  Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2014-03-01       Impact factor: 4.130

10.  Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Authors:  Sophie Langner-Lemercier; Caroline Houillier; Carole Soussain; Hervé Ghesquières; Olivier Chinot; Luc Taillandier; Pierre Soubeyran; Thierry Lamy; Franck Morschhauser; Alexandra Benouaich-Amiel; Guido Ahle; Marie-Pierre Moles-Moreau; Cécile Moluçon-Chabrot; Pascal Bourquard; Ghandi Damaj; Fabrice Jardin; Delphine Larrieu; Emmanuel Gyan; Remy Gressin; Arnaud Jaccard; Sylvain Choquet; Annie Brion; Olivier Casasnovas; Philippe Colin; Oumedaly Reman; Adrian Tempescul; Jean-Pierre Marolleau; Michel Fabbro; Florian Naudet; Khê Hoang-Xuan; Roch Houot
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.